Sr. Director, Skeletal Muscle and Cardiometabolic Diseases at Valo Health

New York, New York, United States

Apply Now

Not SpecifiedCompensation

Senior (5 to 8 years), Expert & Leadership (9+ years)Experience Level

Full TimeJob Type

UnknownVisa

Biotechnology, PharmaceuticalsIndustries

Requirements

PhD in Biological Sciences or a related field with 13+ years of experience (can include postdoctoral experience)
Broad expertise in skeletal muscle biology, ideally with a focus on peripheral energy metabolism, obesity, and/or cardiovascular disease
Experience leading small molecule drug discovery project teams
Experience building and leading high-functioning teams of multiple skill levels
Track record of impactful science
Deep proficiency in skeletal muscle biology and metabolic disease (expertise in cardiac biology desired)
Background in drug discovery
Passion for translating human data insights to develop new therapies for complex diseases

Responsibilities

Lead, manage, and provide scientific mentorship to a team of biologists at multiple skill levels, including project leaders and bench scientists
Generate hypothesis-driven experimental plans and proposals for target validation and drug discovery project execution in close collaboration with data scientists, in vitro pharmacology, chemistry, and other subject matter experts to enable crisp decision making
Serve as biology leader at NY site to guide biology team through drug discovery process from target validation through development candidate stages; serve as research project leader on small molecule drug discovery teams
Closely collaborate with scientists from Lexington site and remote workers
Provide thought leadership and guidance on skeletal muscle biology as it relates to obesity & T2DM as well as cardiovascular disease biology, staying abreast of emerging trends and advancements in the field
Lead a team of scientists to develop and execute strategies using human cell assays to validate novel targets and lead drug discovery projects stemming from these target validation efforts
Deliver validation data packages, lead and progress drug discovery programs, and present to internal and external stakeholders
Collaborate with subject matter experts, computational scientists, and engineers
Contribute as a subject matter expert to the development of research hypotheses that will shape Valo’s target discovery strategy

Skills

skeletal muscle biology

metabolic disease

cardiac biology

drug discovery

target validation

human cell assays

obesity

type 2 diabetes

cardiovascular diseases

AI/ML

translational models

Valo Health

Drug discovery using machine learning technology

About Valo Health

Valo Health focuses on drug discovery and development in the biopharmaceutical sector, utilizing advanced technology to create new drugs and therapies. The company employs its proprietary Opal Computational platform, which integrates machine learning, tissue biology, and patient data to streamline the drug discovery process. This platform allows Valo Health to identify potential drug candidates more quickly and accurately than traditional methods. Valo Health differentiates itself from competitors by combining technology with life sciences, fostering a collaborative culture that addresses significant challenges in drug development. The company's goal is to improve health outcomes for patients worldwide by delivering effective solutions through partnerships with pharmaceutical companies and research institutions.

Boston, MassachusettsHeadquarters

2019Year Founded

$474.2MTotal Funding

LATE_VCCompany Stage

AI & Machine Learning, BiotechnologyIndustries

51-200Employees

Risks

Leadership changes may impact Valo's strategic direction and decision-making.

Heavy reliance on Novo Nordisk partnership poses financial risks if expectations aren't met.

Intensifying competition in AI-driven drug discovery could challenge Valo's market position.

Differentiation

Valo Health integrates AI and human-centric data for drug discovery and development.

The Opal Computational Platform offers an end-to-end solution for drug discovery.

Valo's approach combines machine learning, tissue biology, and patient data for precision therapeutics.

Upsides

Valo's partnership with Novo Nordisk could yield up to $4.6 billion in milestone payments.

The growing market for AI-driven drug discovery platforms supports Valo's business model.

Strategic partnerships with pharmaceutical companies enhance Valo's revenue and market reach.

Land your dream remote job 3x faster with AI

Try Jobo Free